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Abstract
Background: Danhong injection (DHI) has been widely prescribed to patients with acute ischemic stroke (AIS).
However, due to methodological deficiencies, previous research has not yet provided rigorous evidence to support
the use of DHI in the treatment of AIS. Therefore, we designed this multicenter, randomized, controlled, and
double-blind trial to evaluate the efficacy and safety of DHI for AIS.
Methods/Design: It is a randomized, multicenter, double-blind, placebo-controlled, adaptive clinical trial. A total of
864 eligible patients will be randomized into either the DHI or placebo group in a 2:1 ratio. All patients will be
given the standard medical care as recommended by guidelines. Participants will undergo a 2-week treatment
regimen and 76-day follow-up period. The primary outcome is the proportion of patients with a favorable outcome,
defined as a score of 0–1 on the modified Rankin scale at day 90. Secondary outcomes include a change in the
total score of the Chinese medicine symptom scales of “Xueyu Zheng” (blood stasis syndrome), the proportion of
patients with a Barthel Index score of ≥90, the proportion of patients with an improvement in NIHSS score of ≥4 or
NIHSS score of 0–1, quality of life measured by the EQ-5D scale, etc. Safety outcomes such as global disability (mRS ≥3)
at day 90 will also be assessed. The changes in mRNA and microRNA profiles in 96 patients selected from certain
centers will also be assessed. As this is an adaptive design, two interim analyses are prospectively planned, which will
be carried out after one-third and two-thirds of patients have completed the trial, respectively. Based on the results of
the interim analyses, the Data Monitoring Committee (DMC) will decide how to modify the study.
Discussion: This trial will provide high-quality evidence for DHI in treatment of AIS.
Trial registration: Clinical Trials.gov NCT01677208 (Date of registration 22 December 2012).
Keywords: Acute ischemic stroke, Danhong injection, Chinese medicine, Randomized controlled trial
Background
Acute ischemic stroke (AIS), characterized by an occlu-
sion of the cerebral artery, is one of the leading causes of
mortality, long-term disability, and morbidity. Thrombo-
lytic therapy with intravenous tissue plasminogen activa-
tor (tPA), which remains the only therapeutic drug for
AIS approved by the US Food and Drug Administration,
is limited by the narrow time window of thrombolysis,
bleeding complications, or high costs [1]. Other treatment
strategies mainly utilize therapeutic agents to prevent or
reduce cell damage from ischemia [2]. Hundreds of neuro-
protective agents for ischemic stroke have reached clinical
trials, but no optimal drugs for the clinical treatment of
AIS have yet been developed [3]. This leads us to search
for novel therapeutic approaches, and to investigate
whether natural compounds extracted from herbs may be
an alternative option to improve treatment for AIS [4].
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Danhong injection (DHI), extracted from Radix Sal-
viae miltiorrhizae (Danshen) and Flos Carthami tinctorii
(Honghua), is a Chinese medicinal product approved by
the China Food and Drug Administration (CFDA), and
it is widely used in China for treating AIS [5]. Previous
studies demonstrated the neuroprotective efficacy of
DHI in rat models with cerebral ischemic-reperfusion
injury [6, 7], and that the underlying pharmacological
mechanisms might involve anti-inflammatory, anti-
coagulant, antithrombotic, antifibrinolytic, and antioxi-
dant activities [8]. A number of clinical studies also
supported the efficacy and safety of DHI in the manage-
ment of AIS, but due to the methodological deficiencies
of inadequate randomization, no double blinding, no
placebo control, or incomplete outcome data, the quality
of these studies was assessed as generally low [9]. There
is a lack of critically appraised evidence such as well-
designed randomized controlled trials (RCTs) to justify
its clinical use and recommendation. Thus, we aim to
investigate the efficacy and safety of DHI in the treat-
ment of AIS in a well-designed, randomized, multicenter,
double-blind and placebo-controlled trial. The trial was




This is an adaptive design, multicenter, randomized,
double-blind, placebo-controlled, superiority trial of DHI
in the treatment of acute ischemic stroke. Eligible pa-
tients are randomly assigned in a 2:1 ratio into the DHI
group or placebo control group (Fig. 1, Table 1). An
adaptive design will be applied; if the superiority of DHI
is observed at the time of the interim analysis, the trial
can be terminated early.
Participant eligibility
To be fully eligible for participation in the trial, acute
ischemic stroke inpatients must meet all of the following
inclusion criteria and not meet any of the following
exclusion criteria.
Inclusion criteria
1. Female or male inpatients.
2. Aged 18–70 years.
3. Clinical diagnosis of ischemic stroke causing a
measurable neurological deficit defined as
impairment of language, motor function, cognition
and/or gaze, vision or neglect. Ischemic stroke is
defined as an event characterized by the sudden
onset of an acute focal neurologic deficit presumed
to be due to cerebral ischemia after computed
tomography (CT) scan excludes hemorrhage.
4. Clinical diagnosis of “Xueyu Zheng” (blood stasis
syndrome) defined as a total score of Chinese
medicine symptom scales of “Xueyu Zheng” in
ischemic stroke ≥20. The Chinese medicine
symptom scales of “Xueyu Zheng” include the visual
analogue scales (VAS) for the following items: (1)
hemiplegia (0–10), (2) numbness of limbs (0–10), (3)
dark face (0–9), (4) purple or dark lip (0–8), (5)
rough skin (0–4), (6) pain with fixed point (0–5), (7)
purple or dark tongue (0–10), (8) ecchymosis on the
tongue (0–10), (9) purple sublingual vessels (0–10),
(10) sublingual varices (0–8), (11) unsmooth pulse
(0–8), and (12) intermittent pulse (0–1).
5. Onset of symptoms within 1 week prior to initiation
of study drug administration.
6. Clinical diagnosis of cerebral anterior circulation
obstruction.
7. 4 ≤National Institutes of Health Stroke Scale
(NIHSS) score <20.
8. Patients willing to participate voluntarily and to sign
a written informed consent document. Informed
consent will be obtained from each patient or the
subject’s legally authorized representative or
relatives, or deferred where applicable, according to
the regulatory and legal requirements of the
participating centers.
Exclusion criteria
1. Evidence of intracranial hemorrhage (ICH) or other
cerebral diseases (e.g., vascular malformation, tumor,
abscess or multiple sclerosis) on the CT or magnetic
resonance imaging (MRI) scan.
2. Patients who underwent thrombolysis or
endovascular treatment.
3. Known history of allergy or suspected allergy to the
study drug.
4. Fasting blood glucose <2.8 or >16.8 mmol/l or with
severe complications due to diabetes (e.g., peripheral
neuropathy, or diabetic gangrene).
5. Liver function impairment with the value of alanine
aminotransferase (ALT) or aspartate
aminotransaminase (AST) over 1.5-fold the upper
limit of normal range.
6. Renal dysfunction with the value of serum creatinine
over 1.5-fold the upper limit of normal range.
7. Severe cardiac dysfunction on echocardiogram or
the New York Heart Association (NYHA) heart
functional class III or IV.
8. History of prior stroke with a modified Rankin Scale
(mRS) score ≥2.
9. Atrial fibrillation complications.
10.Severe stroke as assessed by appropriate imaging
techniques (e.g., massive cerebral infarction affecting
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more than one lobe of the brain or over one-third of
the blood-supply area of the middle cerebral artery).
11.Legally disabled patients.
12.Hemorrhagic tendency or severe or dangerous
bleeding within the prior 3 months.
13.Suspected alcohol addiction or drug abuse.
14.Severe complications that would make the condition
more complicated as assessed by the investigator.
15.Women who are pregnant, lactating or have a
positive pregnancy test, or women who plan to
become pregnant in the subsequent 6 months.
16.Women who have a menstrual period at baseline.
17.Patients who are participating in other trials or have
participated in other trials within the prior 3 months.
Recruitment
Recruitment into the trial started in December 2012 and
is estimated to end in December 2015. Patients with AIS
will be screened for eligibility according to the inclusion
and exclusion criteria. Patients will be thoroughly in-
formed of the details of the study and its potential bene-
fits and risks. Only those who meet the inclusion criteria
and willingly agree to provide written informed consent
will be included. This study will be conducted in 43
hospitals across China, and the number of hospitals
could be increased after the interim analysis.
Sample size estimation
The proportion of patients who had a favorable out-
come, defined as a modified Rankin Scale (mRS) score
of 0–1, after standard medical care coupled with placebo
or DHI for 90 days was unclear. According to previous
studies [10, 11], the proportion of patients who had a
mRS score of 0–1 was about 28.7–45.2 % when only
treated with placebo, so we estimate the proportion is
45 % when placebo coupled with standard medical care
are used. In this trial, it is hypothesized that an increase
of at least 10 % is of clinical significance for the DHI
group. An adaptive design was selected and EAST5.2
software was used to calculate the statistical sample size.
After calculation, the number of subjects was initially es-
timated to be 703 (one-sided test, α = 0.05, β = 0.2). To
allow for a dropout rate of 20 %, a total of 846 patients
will be recruited. According to the adaptive design, the
sample size may be adjusted after the interim analyses,
which will be carried out when one-third (282) and two-
thirds (564) of patients have completed the trial, respect-
ively. With a 2:1 randomization ratio, the number of
Table 1 Data collection schedule and measures
Period Run-in period Treatment period Follow-up period






Medical examination × × × × × ×
Concomitant medications × × × × × ×
Outcomes
BI scale × × × × × ×
mRS scale × × × × × ×
NIHSS × × × × × ×
Chinese medicine symptom scales of “Xueyu Zheng” × × × × × ×
EQ-5D scale × × × × × ×
Global disability on mRS ×
New-onset major vascular events ×
Overall mortality ×
Incidence of severe hemorrhages ×
Incidence of moderate hemorrhages ×
AEs and SAEs ×
Profiles of microRNA in 60 patients from certain centers × × ×
Profiles of mRNA in 60 patients from certain centers × × ×
UCG ultrasound cardiogram, TOAST Trial of Org 10 172 in Acute Stroke Treatment, BI Barthel Index, mRS modified Rankin Scale, NIHSS National Institutes of Health
Stroke Scale, AEs adverse events, SAEs serious adverse events, microRNA micro-ribonucleic acid, mRNA messenger ribonucleic acid
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participants in the DHI group is 564 and that in the con-
trol group is 282.
Randomization
All participants will be randomized into the DHI interven-
tion group or placebo control group. The randomization
procedure will be performed by the central online
randomization system.
Blinding
All patients, treating physicians and statisticians will be
blinded to group assignment until the end of this trial.
Considering the different colors of DHI and 0.9 % saline,
the dropping bottles will be wrapped in sealed shaded
bags (that cannot be unwrapped during infusion; the in-
tegrity of these bags will be checked after infusion) and
brown infusion devices will be used to conceal the liquid
color. Two full-time nurses who cannot contact each
other will implement the above procedures independ-
ently. One nurse will be responsible for the drug prepar-
ation and sealing the dropping bottles with the shaded
brown bags in a designated transfusion room; while the
other nurse will bring the prepared drugs from the
transfusion room to the infusion nurse and supervise the
Fig. 1 The flow diagram of this trial
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infusion process to ensure the drug allocation is blinded
to patients. A confidentiality agreement will be signed by
the two full-time nurses before study initiation.
Interventions
Participants in both intervention and control groups will
be provided with standard medical care throughout the
trial, which should be in strict accordance with the
China Guideline for the Diagnosis and Treatment of
Acute Ischemic Stroke (2010) [12], including medical
care for vital signs, control of temperature, blood pressure
and glucose, improving cerebral blood circulation, anti-
platelet treatment and nutritional supportive care. All of
these routine treatments will be recorded in patients’
medical records as well as their case report forms (CRFs)
in detail. Any concomitant medications that are necessary
to manage any serious underlying disease should also be
recorded in patients’ medical records and their CRFs.
However, any other Chinese herbal medicines or Chinese
patent medicines with the similar pharmacological effect
of DHI will not be allowed throughout the study period.
Intervention group
In addition to standard medical care, participants in the
intervention group will be treated with DHI (40 ml, once
daily) plus 0.9 % normal saline (250 ml, intravenously,
once daily). The infusion rate should be 20–40 drops/
min, and the infusion must be completed within 3 hours.
DHI cannot be mixed with other liquids to be infused.
Control group
In addition to standard medical care, participants in the
placebo group will be treated with the DHI placebo
(0.9 % normal saline, 40 ml, once daily) plus 0.9 % nor-
mal saline (250 ml, intravenously, once daily). The infu-
sion rate should be 20–40 drops/min, and the infusion
must be completed within 3 hours. The DHI placebo
should be prepared by the full-time nurse.
Outcome measures
Primary outcome
The primary outcome is the proportion of patients with
a favorable outcome, defined as a score of 0–1 on the
mRS [13] at day 90. The mRS is a commonly used scale
for measuring the degree of disability or dependence in
the daily activities of people who have suffered a stroke
or other causes of neurological disability. The scale runs
from 0–6, ranging from perfect health without symp-
toms to death.
Secondary outcomes
1. The total score of Chinese medicine symptom scales
of “Xueyu Zheng” (blood stasis syndrome).
2. The proportion of patients with the Barthel Index
(BI) score of ≥90. BI uses ten variables to describe
the activities of daily living (ADL) and mobility, and
a higher number is associated with a better
performance of ADL [14].
3. The proportion of patients with an improvement in
the NIHSS score of ≥4 or the NIHSS score of 0–1.
NIHSS is a tool used to objectively quantify the
impairment caused by stroke. A NIHSS score of 0
typically indicates normal function in that specific
ability, while a higher score is indicative of some
level of impairment [15].
4. The quality of life measured by the EQ-5D scale.
The EQ-5D scale has five standard dimensions to
measure the generalized health-related quality of
life [16].
5. Global disability (mRS ≥3) at day 90.
6. Incidence of new-onset major vascular events within
90 days. Major adverse vascular events include
ischemic stroke, hemorrhagic stroke, transient
ischemic attack, myocardial infarction and
vascular-related death.
The safety of DHI is evaluated by the incidences of global
disability (mRS ≥3) at day 90, new-onset major vascular
events, severe hemorrhages and moderate hemorrhages
within 90 days. The definition of “severe hemorrhages”
and “moderate hemorrhages” is in accordance with the
GUSTO bleeding criteria [17]. Other safety measures in-
clude the overall mortality at day 90. All the adverse
events (AEs) and serious adverse events (SAEs) within
90 days should be observed and documented. Other out-
come measures include the changes in the mRNA and
microRNA profiles in 60 patients selected from certain
centers. An overview of the measurement data collection
schedule is shown in Table 1.
Interim analysis
As an adaptive trial, two interim analyses will be carried
out in a blinded manner after one-third and two-thirds
of patients have completed the trial, respectively. Based
on the statistical results of the interim analyses, the Data
Monitoring Committee (DMC) will decide on the re-
estimation of the sample size and subsequent modifica-
tions to the trial protocol. As the two interim analyses
may lead to an increased possibility of type 1 error, a
Lan-DeMets alpha spending function with an O’Brien-
Fleming boundary will be used to adjust the results.
Safety and adverse events
AEs are undesirable experiences occurring to partici-
pants during the trial, whether or not they are consid-
ered to be related to the experimental treatment. All
AEs during the study must be recorded on the CRF,
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including the nature of each event, time and date of on-
set, duration, intensity, seriousness criteria, an assess-
ment of its cause, the need for specific therapy, the
actions taken and its outcome. According to the severity
of AEs, the investigator will determine whether the par-
ticipant should be withdrawn from the study, and
follow-up procedures should be performed and recorded
in detail. The relationship between the experimental
treatment and the AEs should be assessed and recorded
by the investigator.
A SAE is defined as any untoward occurrence or effect
that causes death, is life-threatening, requires prolonged
hospitalization, results in persistent significant disability,
or leads to a congenital anomaly or birth defect. If a
SAE occurs, the investigator must immediately report it
to the principal investigator and the ethics committee,
and record it on the CRF with a signature and date. The
classification of the severity of AEs and relationship to
the studied drug are conducted according to our previ-
ous study [18].
Data collection and management
An overview of study visits and data collection schedule
of this study is shown in Table 1. All data will be re-
corded by trained clinical investigators in a standardized
electronic case report form (e-CRF) via the Brightech-
Magnsoft Clinical Information Management Systems
(CIMS, Brightech-Magnsoft Inc., Somerset, NJ, USA).
To ensure the accuracy and reliability of the data, the
study monitor will verify and cross-check the eCRFs
against the investigator’s source document records and
drug-dispensing log. In case of any discrepancies in the
cross-check procedure, the results will be sent to the in-
vestigator for resolution. Except for the treatment code,
any individual identification of the subjects will not be
released until the database is closed.
To guarantee the validity and integrity of the trial de-
sign, three committees have been established by the
multicenter trial coordination group. The first is the
Clinical Trial Guidance Committee, which is responsible
for the study design and the implementation process.
The second is the DMC (also known as DSMB, Data
and Safety Monitoring Board), which will supervise the
data collection process in order to control its quality.
The third is the Outcome Evaluation Committee (OEC),
which will evaluate the key outcomes (including outcome
measurements and AEs) based on clinical expertise.
Statistical analysis
Statistical analysis will be performed by the Statistical
Analysis System (SAS, Version 9.1, SAS Institute Inc.,
Cary, NC, USA). Except for the microRNA and mRNA
profiles, most outcome measurements will be analyzed
using full analysis sets (FAS) and per protocol sets (PPS),
according to intention-to-treat (ITT). Compliance ana-
lysis will be based on the FAS, and analysis of concomi-
tant medications will be based on the safety set (SS).
Analytical statistics to estimate the difference in the
number of participants who have completed or been
withdrawn from the trial between groups will be calcu-
lated. Baseline characteristics will be summarized by
means of simple descriptive statistics. For parametric
tests, the results will be described as mean (standard de-
viation), maximum, minimum, and median, and non-
parametric test median (quartile deviation). Categorical
data will be described by absolute values and proportion.
Enumeration data will be analyzed by chi-square test
(χ2 test) test, Cochran-Mantel-Haenszel (CMH) χ2 test,
Fisher’s exact test, or Wilcoxon rank test. Quantitative
data will be compared by analysis of variance (ANOVA)
and t test. Two-sample t tests will be employed for com-
parison between groups. Paired t test will be used to
analyze significant difference between pre- and post-
treatment. Student-Newman-Keuls (SNK) significance
test will be used for pairwise comparison. Chi-squared
test will be used for nominal categorical data, rank sum
test for ordinal categorical data. The analysis of covari-
ance (ANCOVA) will be used to control potential con-
founding variables. In all analyses, statistical uncertainty
will be expressed by means of 95 % CI.
Efficacy analysis
Primary and secondary efficacy measures will be ana-
lyzed. Any factors impacting efficacy should be taken
into account as covariance, such as age and gender. The
ANCOVA model, Cox’s proportional hazards regression
model, or logistic regression model will be used to assess
treatment effects.
Safety analysis
Safety will be analyzed in terms of the incidence of new-
onset major vascular events within 90 days, overall mor-
tality within 90 days, incidence of severe hemorrhages
within 90 days, incidence of moderate hemorrhages
within 90 days, as well as AEs and SAEs. Safety analysis
will be done in the safety set (SS), defined as a subset of
subjects who were randomized and received at least one
treatment.
Ethical considerations
This trial will be conducted in adherence to the Declar-
ation of Helsinki (Edinburgh 2000). Informed consent will
be obtained from all participants or their legal representa-
tive, in writing, before inclusion in the trial. The trial has
been approved by the local institutional ethics committees
(the Ethics Committee of the Institute of Basic Clinical
Research, China Academy of Chinese Medical Sciences;
the Ethics Committee of Chinese PLA General Hospital).
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The ethics committees of the clinical centers which
approved this study are listed in Additional file 1.
Discussion
Although a number of trials on DHI in the treatment of
AIS have been published, the methodological deficien-
cies of these trials such as inadequate randomization, no
double blinding, no placebo control, and incomplete
outcome data may have lead to various biases, so there
is still a lack of robust evidence to prove its efficacy. It is
widely accepted that a well-designed RCT is the gold
standard for evaluating the clinical efficacy and safety of
Chinese medicine (CM). To the best of our knowledge,
this study is the first rigorously designed RCT to evalu-
ate the efficacy and safety of DHI for AIS. In this trial, a
central online randomization system and triple-blind
method are used to avoid the potential selection and de-
tection biases. Although there are limitations of placebo
control in CM research due to the unique characteristics
of herbal medicines or CM such as color, appearance,
odor and properties, the placebo control in this study
will be strictly implemented. The wrapped dropping bot-
tles and brown transfusion devices will be used to facilitate
the placebo control, making the treatment seemingly iden-
tical between the DHI and placebo groups, so the poten-
tial placebo effect will be excluded. Besides, an adaptive
design, which includes a prospectively planned opportun-
ity for modification of the trial design, has been adopted
to improve the efficiency of the study (e.g., shorter dur-
ation, or fewer patients) [19]. Moreover, the add-on study
design, which can be summarized as “A+ B versus B”
model, will also be applied in this trial. The routine treat-
ment will be administered in both the DHI and placebo
groups, so as to provide reliable evidence for DHI as an
effective add-on therapy for patients with AIS.
Both doctor-reported outcome (DRO) and patient-
reported outcome (PRO) models will be used as out-
come measures in this study. In addition to the doctor’s
observation, patient-centered outcomes focusing on pa-
tient’s quality of life and relief of symptoms will also be
applied. It is believed that CM may demonstrate superi-
orities in terms of alleviating symptoms and improving
quality of life. In traditional Chinese medicine (TCM),
disease treatments are based on syndrome (Zheng in
Chinese) differentiation, and improvement of the syn-
drome often indicates better prognosis of the disease. It
is proposed that blood stasis syndrome (Xueyu Zheng) is
the most common type of AIS [20]. Therefore, the TCM
syndrome score is used as an outcome measure, which
mainly focuses on the improvement of patient symp-
toms. DHI is an approved Chinese medicinal product
extracted from Radix Salviae miltiorrhizae and Flos
carthami, which can produce a remarkable curative ef-
fect on Xueyu Zheng. Several studies have validated the
vascular-protective effects of DHI [21–24]. Based on the
theoretical and clinical evidence, DHI may have a great
therapeutic value in real-world clinical practice.
There are also some limitations in this trial. First, be-
cause of the relatively short follow-up period, it is not
possible to assess the long-term effects of DHI on the
primary outcome, and the potential role of DHI for re-
ducing major vascular events and overall mortality in
the longer term will remain unknown. Second, due to
the absence of a “head-to-head” design, this study can
only demonstrate the complementary effect of DHI, but
still cannot draw a definite conclusion regarding whether
DHI can serve as an alternative therapy for AIS. There-
fore, well-designed RCTs comparing DHI versus conven-
tional anti-ischemia therapy with a longer-term follow-up
are warranted in the future.
Trial status
The study began recruiting patients in 2012. The trial is
currently recruiting patients.
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